



UPDATED PROGRAM – CHANGED TO ONLINE ONLY

1st Nordic AML Group Meeting 2022 and Annual meeting of the Swedish AML Group 2022

Dates: January 20-21, 2022

Zoom link for both days: <https://uu-se.zoom.us/j/63144421705>

Thursday, January 20: Nordic AML Group Scientific Meeting

11:00-12:00 SCIENTIFIC SESSION I:

(Chairs: Bjørn Tore Gjertsen, Norway and Vladimir Lazarevic, Sweden)

11:00-11:05 Welcome – Bjørn Tore Gjertsen, Bergen and Vladimir Lazarevic, Lund

11:05-11:50 Keynote: Lars Bullinger, Berlin: Harmony and emerging AML therapies

11:50-12:00 Discussion and concluding remarks

12:00-13:00 *Break for lunch*

13:00-13:30 THE NORDIC AML GROUP – WORDS FROM THE CHAIRMAN

Overview and future goals of the newly formed Nordic AML Group (Bjørn Tore Gjertsen)

13:30-15:15 TRIAL WORKING GROUP:

(Chairs: Kim Theilgaard-Mönch, Denmark and Mika Kontro, Finland)

13:30-13:40 Kim Theilgaard-Mönch, Copenhagen: Introduction of the Trial Working Group of the NAMLG

13:40-14:25 Keynote: Gerwin Huls, HOVON: The perspective of HOVON on AML studies in the era of precision medicine

14:25-14:50 Gro Gausdal, Bergen Bio: AXL role in AML/ MDS, biology and targeting AXL with Bemcentinib
Claudia Gorcea-Carson, BerGenBio: The 003 study with bemcentinb in AML/HR MDS: overview and preliminary results

14:50-15:15 Mika Kontro, Helsinki: Interim results from the VenEx trial

15:15 – 15:45 *Leg stretch / coffee*

15:45-17:30 SCIENTIFIC WORKING GROUP:

(Chairs: Sören Lehmann, Sweden and Caroline Heckman, Finland)

15:45-15:55 Sören Lehman, Uppsala: Presentation of the Scientific Working Group of the NAMLG

15:55-16:40 Keynote: Jude Fitzgibbon, London: Multi-Omic profiling in Poor Risk AML – is it helping?

16:40-17:05 Caroline Heckman, Helsinki: Pharmacological inhibition of AML at the single cell level

17:05-17:30 Kimmo Porkka, Helsinki: Data-driven management of AML

Annual meeting of the Swedish AML Group 2022

Friday, January 21: Swedish AML Group meeting

08:30-09:10 ANNUAL MEETING OF SWEDISH AML GROUP

08:30-09:00 Swedish AML Steering Group meeting (in Swedish)

09:00-09:10 Report of activities from the Swedish AML Group (in Swedish)

09:10-09:25 *Leg stretch / coffee*

09:25-09:30 Welcome (Vladimir Lazarevic, Lund)

09:30-11:00 Translational session: Genetic MRD and its implications for clinical decision-making (chairs: Linda Fogelstrand, Göteborg and Martin Jädersten, Stockholm)

09:30-10:15 Keynote lecture: Genetic MRD of non-DTA-mutations (Felicitas Thol, Hannover)

10:15-11:00 Clinical decision-making according to MRD; Panel discussion and cases
(Felicitas Thol, Linda Fogelstrand, Martin Jädersten, and Jörg Cammenga, Lund)

11:00-11:10 *Leg stretch / coffee*

11:10-12:00 Swedish AML registry and related studies

(chairs: Anna Thunström, Umeå and Jörg Cammenga, Linköping)

11:10-11:30 Report from the Swedish AML registry (Gunnar Juliusson, Lund)

11:30-11:45 Novel APL risk score (Albin Österroos, Uppsala)

11:45-12:00 Update on therapy-related AML (Sören Lehmann, Uppsala)

12:00-13:00 *Break for lunch*

13:00-13:50 Clinical focus session

(chair: Kristina Myhr-Eriksson, Luleå)

13:00-13:30 Myeloid sarcoma – an overview. Anna Eriksson, Uppsala

13:30-13:50 Case presentation and discussion. Janaki Brolin, Karlstad

13:50-14:00 *Leg stretch / coffee*

14:00-15:15 Clinical AML trials

(chairs: Lovisa Vennström, Göteborg and Christer Nilsson, Stockholm)

14:00-14:20 HEAT-AML, trial update (Martin Jädersten, Stockholm)

14:20-14:40 Germline predisposition study (Panagiotis Baliakas, Uppsala)

14:40-14:55 HOVON 150 and 156 (Martin Höglund, Uppsala)

14:55-15:15 Overview of other studies ongoing and in pipeline/study proposals (Stefan Deneberg, Stockholm)

15:15-15:30 Concluding remarks (Vladimir Lazarevic)